Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Long-term changes in serum cholesterol level does not influence the progression of coronary calcification.

Tenenbaum A, Shemesh J, Koren-Morag N, Fisman EZ, Adler Y, Goldenberg I, Tanne D, Hay I, Schwammenthal E, Motro M.

Int J Cardiol. 2011 Jul 15;150(2):130-4. doi: 10.1016/j.ijcard.2010.03.001. Epub 2010 Mar 29.

PMID:
20350769
2.

Accelerated progression of coronary calcification: four-year follow-up in patients with stable coronary artery disease.

Shemesh J, Koren-Morag N, Apter S, Rozenman J, Kirwan BA, Itzchak Y, Motro M.

Radiology. 2004 Oct;233(1):201-9. Epub 2004 Aug 27.

PMID:
15333771
4.

An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis.

Stompór T, Pasowicz M, Sulłowicz W, Dembińska-Kieć A, Janda K, Wójcik K, Tracz W, Zdzienicka A, Klimeczek P, Janusz-Grzybowska E.

Am J Kidney Dis. 2003 Jan;41(1):203-11.

PMID:
12500238
5.

Oral calcium supplements do not affect the progression of aortic valve calcification or coronary artery calcification.

Bhakta M, Bruce C, Messika-Zeitoun D, Bielak L, Sheedy PF, Peyser P, Sarano M.

J Am Board Fam Med. 2009 Nov-Dec;22(6):610-6. doi: 10.3122/jabfm.2009.06.080217. Erratum in: J Am Board Fam Med. 2012 Mar;25(2):262.

6.

HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.

Tani S, Nagao K, Hirayama A.

Am J Cardiovasc Drugs. 2011 Dec 1;11(6):411-7. doi: 10.2165/11594620-000000000-00000.

PMID:
22149320
7.

Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients.

Kurnatowska I, Grzelak P, Kaczmarska M, Stefańczyk L, Nowicki M.

Nephron Clin Pract. 2011;117(4):c297-304. doi: 10.1159/000321169. Epub 2010 Sep 22.

PMID:
20861651
8.

Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.

Schmermund A, Achenbach S, Budde T, Buziashvili Y, Förster A, Friedrich G, Henein M, Kerkhoff G, Knollmann F, Kukharchuk V, Lahiri A, Leischik R, Moshage W, Schartl M, Siffert W, Steinhagen-Thiessen E, Sinitsyn V, Vogt A, Wiedeking B, Erbel R.

Circulation. 2006 Jan 24;113(3):427-37. Epub 2006 Jan 16.

9.

Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis.

Stompór TP, Pasowicz M, Sułowicz W, Dembińska-Kieć A, Janda K, Wójcik K, Tracz W, Zdzienicka A, Konieczyńska M, Klimeczek P, Janusz-Grzybowska E.

Am J Kidney Dis. 2004 Sep;44(3):517-28.

PMID:
15332225
10.

Effect of statin treatment on aortic valve and coronary artery calcification.

Mohler ER 3rd, Wang H, Medenilla E, Scott C.

J Heart Valve Dis. 2007 Jul;16(4):378-86.

PMID:
17702362
11.

Components of the insulin resistance syndrome are associated with progression of atherosclerosis in non-grafted arteries 5 years after coronary artery bypass surgery.

Korpilahti K, Syvänne M, Engblom E, Hämäläinen H, Puukka P, Rönnemaa T.

Eur Heart J. 1998 May;19(5):711-9.

PMID:
9717003
12.

Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors.

Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, Strathdee SA, Nelson KE, Wu KC, Chen S, Tong W, Lai S.

Am Heart J. 2002 Oct;144(4):642-8.

PMID:
12360160
13.

Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.

White CW, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, Geller NL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Rosenberg Y, Terrin ML; Post Coronary Artery Bypass Graft Trial Investigators.

Circulation. 2001 Nov 27;104(22):2660-5.

14.

Influence of a lipid-lowering therapy on calcified and noncalcified coronary plaques monitored by multislice detector computed tomography: results of the New Age II Pilot Study.

Burgstahler C, Reimann A, Beck T, Kuettner A, Baumann D, Heuschmid M, Brodoefel H, Claussen CD, Kopp AF, Schroeder S.

Invest Radiol. 2007 Mar;42(3):189-95.

PMID:
17287649
15.

The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.

Sakamoto K, Sakamoto T, Ogawa H; Kumamoto Joint Research on Hypercholesterolemia Investigators.

Clin Ther. 2006 Jul;28(7):1012-21.

PMID:
16990079
16.

Novel atherogenesis markers for identification of patients with a multivessel coronary artery disease.

Krecki R, Drozdz J, Szcześniak P, Orszulak-Michalak D, Krzemińska-Pakuła M.

Kardiol Pol. 2008 Nov;66(11):1173-80; discussion 1181-2.

19.

Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.

Abulhul E, McDonald K, Martos R, Phelan D, Spiers JP, Hennessy M, Baugh J, Watson C, O'Loughlin C, Ledwidge M.

Clin Ther. 2012 Jan;34(1):91-100. doi: 10.1016/j.clinthera.2011.11.002. Epub 2011 Dec 9.

PMID:
22154198
20.

Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels.

Liang KW, Lee WJ, Lee WL, Chen YT, Ting CT, Sheu WH.

Clin Chim Acta. 2008 Feb;388(1-2):41-5. Epub 2007 Oct 10.

PMID:
17967444

Supplemental Content

Support Center